Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895257 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1AADATPOLB | |
| SCHEMBL7053032 | 0.74 | — | — | |
| SCHEMBL3823746 | 0.72 | ALDH1A1 (0.55) | ALDH1A1TDP1POLB | |
| SCHEMBL44531 | 0.69 | TDP1 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL10565073 | 0.69 | TDP1 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL10565064 | 0.69 | TDP1 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL16450801 | 0.69 | — | — | |
| SCHEMBL20983815 | 0.67 | POLB (0.37) | ALDH1A1TDP1POLB | |
| SCHEMBL11057214 | 0.67 | MEN1 (0.36) | — | |
| SCHEMBL9612235 | 0.67 | ALDH1A1 (0.34) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | STEMLINE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4125872-A1 | SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY | Stemline Therapeutics Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4074704-A1 | QUINOLINE COMPOUNDS WITH ANTI-CANCER ACTIVITY | CanBas Co., Ltd. (JP) | 2022-10-19 | — | — | EP | disclosed |
| EP-3567035-B1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021194954-A1 | SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY | STEMLINE THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| CN-107376989-B | Cu-AEI molecular sieve catalyst synthesis and application | 中触媒新材料股份有限公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-2152692-B9 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO LTD (JP) | 2020-03-25 | — | — | EP | disclosed |
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3088397-B1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180081277-A1 | PATTERN FORMING METHOD, RESIST PATTERN, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND COMPOSITION FOR FORMING UPPER LAYER FILM | FUJIFILM CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-1342715-B1 | Process for producing oximes using nitirites | DAICEL CHEM (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-7034184-B2 | Process for producing azine compounds and oxime compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20050080289-A1 | Process for producing dicarboxylic acid | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1342714-B1 | Process for producing azine compounds and oxime compounds | DAICEL CHEM (JP) | 2005-01-26 | — | — | EP | disclosed |
| EP-1471047-A1 | PROCESS FOR PRODUCING DICARBOXYLIC ACID | Daicel Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6768023-B2 | REACTING AN ESTER OR SALT OF NITROUS ACID WITH A COMPOUND THAT GENERATES A FREE RADICAL IN THE PRESENCE OF A NITROGEN CONTAINING CYCLIC COMPOUND CONTAINING AN N-OXY OR -HYDROXY IMIDE GROUP; FORMING OXIMES, NITRO COMPOUNDS, AND KETONES | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-07-27 | — | — | US | disclosed |
| US-20030204084-A1 | Process for producing azine compounds and oxime compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| US-20030171618-A1 | Process for producing organic compounds using nitrites | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1342715-A2 | Process for producing oximes using nitirites | Daicel Chemical Industries, Ltd. (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1342714-A1 | Process for producing azine compounds and oxime compounds | Daicel Chemical Industries, Ltd. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080289-A1 | Process for producing dicarboxylic acid | OGDH, MCCC2, PCCA | ALDH1A1 3529/4885TDP1 2649/4885AADAT 843/4885 |
| US-20030204084-A1 | Process for producing azine compounds and oxime compounds | CBR1, DAO, ALKBH2 | ALDH1A1 848/4885TDP1 4050/4885AADAT 1061/4885 |
| US-20030171618-A1 | Process for producing organic compounds using nitrites | NOS1, NOS2, NOS3 | ALDH1A1 327/4885TDP1 1460/4885AADAT 3197/4885 |
| US-20230158005-A1 | Substituted Azole Dione Compounds with Antiviral Activity | MAVS, DDX18, ZC3HAV1 | ALDH1A1 1388/4885TDP1 1065/4885AADAT 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.